ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0331

Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity

Hiroki Yamaguchi1, Yoriko Ando1, Mika Mizunuma1, Masamichi Inami2, Kenichi Suzumura2 and Yuki Ichikawa1, 1Craif Inc., Nagoya, Japan, 2Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba, Japan

Meeting: ACR Convergence 2021

Keywords: Bioinformatics, Biomarkers, Micro-RNA, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, immune complex deposition, and heterogeneous clinical manifestations affecting many organs, including the skin, joints, the central nervous system, and the kidneys. Once clinical symptoms have developed, prompt diagnosis and proper management of SLE remain great challenges to physicians. Due to the heterogeneity of immune dysregulation, the severity and progression of the disease largely varies among patients, while no single biomarker has emerged as a surrogate for disease activity or severity of SLE.
Recently, evidence indicates that exosomes play important roles in immune modulation and are associated with the immune pathogenesis of autoimmune diseases, including systemic lupus erythematosus. Exosomes are 20-150 nm-sized vesicles that function as a vital medium for cellular communication. It encapsulates microRNAs (miRNAs), a non-coding RNA, which are known as gene expression modulators, and strongly relates to physiological conditions like disease status. Here, we have developed a mass-producible and sterilizable nanowire-based device (nanowire device) that can extract urinary exosomal microRNAs efficiently. Our objective of the research is to extract urinal exosomes and detect microRNAs using nanowire devices, and identify biomarkers which could support SLE diagnosis and identify its status and severity.

Methods: Exosomes were extracted by nanowire device and miRNA expression was measured from urine samples of 30 SLE patients and 30 non-SLE donors using a microarray to yield comprehensive microRNA expression profiles.

Results: Differential expression analysis revealed 242 biomarker miRNAs candidates,160 up-regulated and 82 down-regulated in SLE patients compared with healthy individuals. Down-regulation patterns were related to the severity of the disease, revealing severity-specific miRNAs.Pathway analyses revealed the candidate miRNAs showed relation with genes strongly related to SLE including JAK-STAT and BCL pathways. Moreover, we adopted a support vector machine model and successfully developed a classifier to detect SLE based on these miRNA expression patterns, which showed remarkably high sensitivity (0.89) and specificity (0.82).

Conclusion: These findings show that urinary miRNAs may provide insights into SLE pathogenesis, and could be a potential biomarker of disease activity, paving the way to a liquid biopsy for individualized SLE treatment.


Disclosures: H. Yamaguchi, Craif Inc., 3; Y. Ando, Craif inc., 3; M. Mizunuma, Craif.inc, 3, 4; M. Inami, Astellas Pharma Inc., 3; K. Suzumura, Astellas Pharma Inc., 3; Y. Ichikawa, Craif inc., 4.

To cite this abstract in AMA style:

Yamaguchi H, Ando Y, Mizunuma M, Inami M, Suzumura K, Ichikawa Y. Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/urinary-micrornas-as-systemic-lupus-erythematosus-biomarkers-and-its-potential-for-accurate-assessment-of-disease-severity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-micrornas-as-systemic-lupus-erythematosus-biomarkers-and-its-potential-for-accurate-assessment-of-disease-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology